President Donald Trump's budget blueprint sparked concerns among multiple stakeholders and legislators Thursday (March 16) for putting stable appropriations funding and already-negotiated FDA user fee agreements at risk. Trump's proposed “skinny budget” asks industry to pay double the amount of user fees to fully fund FDA pre-market approvals in exchange for administrative reforms to speed new products to market. Industry trade groups said the already-negotiated user fee agreements are critical programs that benefit FDA, industry and patients. They emphasized they...